User:Ahmed Zaghw

Idiopathic interstitial pneumonia

lolo	lolo2	lolo3
koko1	koko2	koko3

Class I

"1. High-intensity statin therapy should be initiated or continued as first-line therapy in women and men ≤75 years of age who have clinical ASCVD, unless contraindicated.(Level of Evidence: A)"

"2. In individuals with clinical ASCVD* in whom high-intensity statin therapy would otherwise be used, when high-intensity statin therapy is contraindicated† or when characteristics predisposing to statin-associated adverse effects are present, moderate-intensity statin should be used as the second option if tolerated.(Level of Evidence: A)"

Risk category	LDL goal, mg/dL	Non-HDL goal, mg/dL
CHD and CHD risk equivalent (10 year risk for CHD is >20%)	< 100	< 130
Multiple (2+) risk factor (10 year risk for CHD is <20%)	< 130	< 160
0-1 risk factors	< 160	< 190

ATP III LDL cholesterol and Non-HDL cholesterol goals

Class I

"1. Individuals with LDL–C ≥190 mg/dL or triglycerides ≥500 mg/dL should be evaluated for secondary causes of hyperlipidemia.(Level of Evidence: B)"

"2. Adults ≥21 years of age with primary LDL–C ≥190 mg/dL should be treated with statin therapy (10-year ASCVD risk estimation is not required): Use high-intensity statin therapy unless contraindicated. For individuals unable to tolerate high-intensity statin therapy, use the maximum tolerated statin intensity.(Level of Evidence: B)"